Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Assessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2020 – 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The global sales for migraine drugs have been valued at $4.6 billion in 2020 with a CAGR of more than 9%. The US has dominated the migraine market, contributing to more than 80% of the sales in the seven major pharmaceutical markets (7MM) covered – the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. A high market share in US is attributed to the large migraine prevalent population, the costliness of branded drugs, and the number of drugs marketed exclusively in the US compared to other countries in the 7MM. Steady growth has been observed across the European countries over the forecast period.
Overview of the migraine drugs market
For more insights on this report, download a free report sample
What are the market dynamics and market barriers for the migraine drug market?
Major drivers of the growth within the migraine drugs market include the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs) as a preventive migraine treatment. These drug classes will claim significant patient share across 7MM during the forecast period. The number of 12-month total prevalent cases of migraine is expected to increase during the forecast period, which will lead to an increase in the diagnosed and treated population and drive sales.
Major barriers to the growth of the market include the high use of generic products that are expected to continue throughout the forecast period, the patent expiration of Onzetra Xsail, Trokendi XR, and Reyvow that will lead to cheap generics flooding the market and negatively impacting the branded sales. The ACOTs of anti-CGRP mAbs are significantly higher when compared with the cost of generic triptans and generic oral preventives (antihypertensives, anti-epileptics, and antidepressants).
This may restrict uptake, with payers and physicians’ preference being to prescribe cheaper orally administered alternatives when possible.
12-month total prevalent cases of migraine, 7MM, both sexes, 2020
For more insights, download a free report sample
How has the global COVID-19 pandemic impacted the migraine drugs market?
The neurologic manifestations of COVID-19 suggest a potential entry of the virus into the nervous system via the olfactory groove or the bloodstream. There is strong evidence of COVID-19 mortality being associated with cardiac and pulmonary diseases. Additionally, migraine leads to a higher burden of vascular diseases, which places people with migraine at higher risk of poor COVID-19 outcomes. Acute symptoms of COVID-19 such as fever, sleep disturbance, and dehydration may trigger a migraine episode. Headaches due to COVID-19 were described as pulsating, pressing, or stabbing in quality, and were mostly bilateral, of longer duration, resistant to analgesia, and are more common in males. This makes people with migraine particularly vulnerable to the chronic and indirect effects of the pandemic, including low mood, post-viral fatigue, anxiety, and depression.
What is the disease management and treatment overview for migraine?
Episodic migraine
In cases where patients suffer from a small number (one or two) migraines per month, nonsteroidal anti-inflammatory drugs (NSAIDs) are being prescribed and are taken upon the onset of a migraine. However, in patients with more frequent migraine days, triptans are being prescribed as first-line treatments and can be used in combination with NSAIDs.
In cases where the patient experiences four or more attacks per month, physicians look to prescribe an oral preventive treatment, such as antidepressants, anti-epileptics, and beta-blockers. The specific types of preventive treatment vary among countries in the 7MM.
Chronic migraine
The initial treatment of chronic migraine, classified as 15 or more migraines per month, aims to reduce the frequency, severity, and duration of migraine attacks. Triptans may be prescribed as acute therapy, but due to the number of migraines suffered by those with chronic migraine, this may lead to MOH. Thus, preventive migraine treatments are usually prescribed immediately to these patients. Again, first-line treatment with oral preventives is personalized based on the patient’s need and the physician’s preference. Antidepressants, anti-epileptics, and beta-blockers are the main classes prescribed as first-line oral preventive therapies.
What are the key players in the migraine drugs market?
Companies such as GlaxoSmithKline, Merck, and Pfizer are the three biggest players in the migraine market with products such as Imitrex, Amerge, Maxalt, and Relpax. Players such as Teva, Amgen, Eli Lilly and Lundbeck are also expected to contribute largely to the market as evidenced by the sales of their respective CGRP-targeting mAbs, Ajovy, Aimovig, Emgality, and Vyepti.
Biohaven is anticipated to remain a strong player in the migraine market with an expanding CGRP-targeting portfolio of small molecules. Furthermore, Axsome therapeutics, Impel Neuropharma, Zosano Pharma, and Satsuma pharmaceuticals are expected to be strong contenders in the migraine market.
Migraine drug market, by key players
For more insights, download a free report sample
Market report scope
Market size (Year – 2020) | $4.6 billion |
Growth rate | CAGR of >9% from 2021 to 2025 |
Base year for estimation | 2020 |
Market segments by country | The US, France, Germany, Italy, Spain, the UK and Japan |
Forecast period | 2021-2025 |
Key players | GlaxoSmithKline, Merck, Pfizer, Teva, Amgen, Eli Lilly and Lundbeck and Biohaven |
Scope
This report provides a comprehensive analysis of the Migraine Drug market-
- Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the migraine therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
The prevalence of migraine is increasing in line with population growth in the 7MM.
Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients’ comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.
The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.
The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.
The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Amgen
Axsome Therapeutics
Biohaven Pharmaceuticals
Bristol-Myers Squibb
Currax Pharmaceuticals
Eli Lilly
Endo International
Exeltis Healthcare
GlaxoSmithKline
H.Lundbeck
Impel NeuroPharma
Merck
Novartis
Old API Wind-down
Pfizer
Teva Pharmaceuticals
Satsuma Pharmaceuticals
Sosei Heptares
Zosano Pharma Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What is the value of the migraine drug market in 2020?
The migraine drug market was valued at $4.6 billion in 2020.
-
What are the key countries in the migraine drug market?
There are seven major pharmaceutical markets (7MM) covered in this report: The US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan.
-
Who are the key market players in the migraine drug market?
GlaxoSmithKline is the leading player in the migraine drug market followed by Merck, Pfizer, Teva, Amgen, Eli Lilly, and Lundbeck, and Biohaven.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.